| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,330 | -4,070 | -4,180 | -4,330 | -4,540 |
| Net Income Growth | +18.18% | +2.63% | +3.46% | +4.63% | +22.79% |
Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.
Fiscal Year End Date: 12/31